These therapies, including T-cell engagers (TCEs), natural killer cell engagers (NKCEs), and phagocyte cell engagers (PCEs), have introduced novel mechanisms of action, such as MHC-independent tumor targeting, immune synapse formation, and modulation of the tumor microenvironment (TME) [4,8,14,86]. Here, HLA-C is linked to neoplasm.